Patents by Inventor Zhixiong Ye

Zhixiong Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11325914
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: May 10, 2022
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
  • Publication number: 20210299128
    Abstract: This invention relates to compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.
    Type: Application
    Filed: March 15, 2021
    Publication date: September 30, 2021
    Inventors: Michael Serrano-Wu, Zhixiong Ye, Kejia Ding
  • Patent number: 10800782
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 13, 2020
    Assignee: Agios Pharmaceutical, Inc.
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
  • Publication number: 20190233424
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Application
    Filed: December 13, 2018
    Publication date: August 1, 2019
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
  • Patent number: 10329298
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: June 25, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
  • Patent number: 10000479
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: June 19, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Rene M. Lemieux, Sheldon Cao, Yue Ding, Zhixiong Ye
  • Publication number: 20180079753
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Application
    Filed: August 30, 2017
    Publication date: March 22, 2018
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
  • Patent number: 9856279
    Abstract: Provided are piperazine compounds of Formula I useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 2, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy M. Travins, Shunqi Yan, Zhixiong Ye
  • Publication number: 20170210749
    Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy M. Travins, Shunqi Yan, Zhixiong Ye
  • Patent number: 9662327
    Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 30, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy Travins, Shunqi Yan, Zhixiong Ye
  • Publication number: 20170137414
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Application
    Filed: March 20, 2015
    Publication date: May 18, 2017
    Applicant: AGIOS Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Rene M. Lemieux, Sheldon Cao, Yue Ding, Zhixiong Ye
  • Publication number: 20160229876
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described here.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy M. Travins, Shunqi Yan, Zhixiong Ye
  • Patent number: 9365545
    Abstract: Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 14, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Robert Zahler, Sheldon Cao, Xiaolei Wang, Zhixiong Ye
  • Publication number: 20160046579
    Abstract: Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 18, 2016
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Robert Zahler, Sheldon Cao, Xiaolei Wang, Zhixiong Ye
  • Publication number: 20150336931
    Abstract: Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 26, 2015
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Robert Zahler, Sheldon Cao, Xiaolei Wang, Zhixiong Ye
  • Patent number: 9108921
    Abstract: Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 18, 2015
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Robert Zahler, Sheldon Cao, Xiaolei Wang, Zhixiong Ye
  • Publication number: 20140288081
    Abstract: Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Giovanni Cianchetta, Janeta Popovici-Muller, Robert Zahler, Sheldon Cao, Xiaolei Wang, Zhixiong Ye
  • Publication number: 20140213580
    Abstract: Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds.
    Type: Application
    Filed: June 18, 2012
    Publication date: July 31, 2014
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy Travins, Shunqi Yan, Zhixiong Ye
  • Publication number: 20140206673
    Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
    Type: Application
    Filed: June 18, 2012
    Publication date: July 24, 2014
    Applicant: AGIOS PHARMACEUTICALS, INC
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy Travins, Shunqi Yan, Zhixiong Ye
  • Publication number: 20110201615
    Abstract: Beta-carboline derivatives of structural formula (I) are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.
    Type: Application
    Filed: October 19, 2009
    Publication date: August 18, 2011
    Inventors: Liangqin Guo, Jian Liu, Ravi P. Nargund, Alexander Pasternak, Lihu Yang, Zhixiong Ye